期刊
JOURNAL OF NEPHROLOGY
卷 26, 期 6, 页码 1105-1113出版社
SPRINGER HEIDELBERG
DOI: 10.5301/jn.5000245
关键词
Arteriosclerosis; Biomarkers; Chronic kidney disease; sTWEAK
资金
- Fondo de Investigaciones Sanitarias
- Instituto de Salud Carlos III
- Ministerio de Sanidad y Consumo [RETICS RD06/0014/0035, PI10/00234, PI10/00072]
- Sociedad Espanola de Arteriosclerosis
- Fundacion Mutua Madrilena
Background: Chronic kidney disease (CKD) is characterized by a high mortality rate, primarily due to cardiovascular disease. Reduced soluble TNF-like weak inducer of apoptosis (sTWEAK) levels have been related with endothelial function in CKD patients. However, there are no data on the relationship between sTWEAK and its scavenger receptor CD163 and atherosclerotic burden in CKD. Methods: A cross-sectional, observational study was conducted in 58 patients with CKD stages 1-3, 86 with CKD stages 4-5, 195 on dialysis and 86 healthy controls. The severity of atherosclerosis was estimated with the atherosclerosis score (AS), combining the results of ankle-brachial index and carotid ultrasound. sTWEAK and CD163 plasma concentrations were measured by ELISA. Results: sTWEAK plasma levels were diminished and CD163 concentrations were increased in patients with CKD compared with controls (sTWEAK: median [interquartile range] 308 pg/mL [258-378] vs. 371 pg/ML [319-455]; p<0.001; and CD 163: 1,047 ng/mL [740-1,495] vs. 540 ng/mL [319-765]; p<0.001; respectively). A weak but statistically significant association between sTWEAK or CD163 and carotid intima-Media thickness (r = -0.109, p = 0.025;,r = 0.179, p<0.001;respectively) was observed. Patients with more severe atherosclerosis presented a higher reduction in sTWEAK concentrations (412 pg/mL. [302-322] vs. 368 pg/mL [351-385]; p<0.001) and a high-er increment in CD163 levels (1,182 ng/mL [1,107-1,258] vs. 826 ng/mL [733-919]; p<0.001). After multivariable analysis, only elevated sTWEAK levels were associated with reduced risk of atherosclerosis (0.34 [0.14-0.86], p = 0.02). Conclusions: A significant reduction in sTWEAK and increment in CD163 plasma levels were observed in patients with more severe atherosclerosis. Our results indicate that sTWEAK could be a novel biomarker of atherosclerotic burden in CKD patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据